文献速递青光眼

青光眼中人筛板细胞通过Yes相关蛋白的基质机械转导

Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2022-01-01

研究比较青光眼供体眼筛板细胞(GLC,n=3)与年龄匹配非青光眼对照(NLC,n=3)的YAP表达与增殖,并将NLC接种于软(4 kPa)和硬(100 kPa)胶原-1包被聚丙烯酰胺水凝胶。GLC细胞YAP基因和总YAP蛋白显著升高(P<0.05)且增殖增加;硬基质上调NLC的YAP表达、核聚集及促纤维化标志物;维替泊芬(2 µM)显著抑制YAP介导的活化和增殖。

要点

  • GLC细胞较NLC细胞YAP基因表达和总YAP蛋白显著升高(P<0.05),增殖显著增加。
  • NLC细胞在100 kPa硬基质上YAP基因和蛋白显著上调,Y357磷酸化增加、S127磷酸化降低,核聚集增加。
  • 维替泊芬(2 µM)在硬基质微环境中仍显著抑制YAP介导的细胞活化和增殖。

核心结论

  • YAP在筛板细胞对衰老和青光眼所致硬化的筛板反应中发挥关键作用,促使其获得促纤维化和增殖表型。
  • YAP是有吸引力的新型治疗靶点,作者认为维替泊芬抑制YAP值得进一步临床研究。

研究设计与样本

  • 实验研究:比较青光眼供体眼来源筛板细胞(GLC,n=3)与年龄匹配非青光眼对照筛板细胞(NLC,n=3)。
  • NLC细胞培养于软(4 kPa)和硬(100 kPa)胶原-1包被聚丙烯酰胺水凝胶基底。
  • 采用定量实时RT-PCR、免疫印迹和免疫荧光显微镜检测YAP及其下游靶点的表达、活性和亚细胞定位;用甲基噻唑基四唑盐法检测增殖。
  • 在含或不含YAP抑制剂维替泊芬(2 µM)条件下检测终点。

主要发现

  • GLC细胞较NLC细胞YAP基因表达和总YAP蛋白显著增加(P<0.05),增殖显著增加。
  • NLC细胞在100 kPa硬基底上YAP基因和蛋白表达显著上调,Y357磷酸化增加、S127磷酸化降低,核聚集增加,结缔组织生长因子转录靶点增加。
  • 肌成纤维细胞标志物α-平滑肌肌动蛋白(α-SMA)和I型胶原α1(Col1A1)增加。
  • 增殖率在50 kPa基底和细胞培养塑料上升高。
  • 维替泊芬(2 µM)在硬化的微环境中仍显著抑制YAP介导的细胞活化和增殖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Extracellular matrix stiffening is characteristic of both aging and glaucoma, and acts as a promoter and perpetuator of pathological fibrotic remodeling. Here, we investigate the role of a mechanosensitive transcriptional coactivator, Yes-associated protein (YAP), a downstream effector of multiple signaling pathways, in lamina cribrosa (LC) cell activation to a profibrotic, glaucomatous state. METHODS: LC cells isolated from glaucomatous human donor eyes (GLC; n = 3) were compared to LC cells from age-matched nonglaucomatous controls (NLC; n = 3) to determine differential YAP expression, protein levels, and proliferation rates. NLC cells were then cultured on soft (4 kPa), and stiff (100 kPa), collagen-1 coated polyacrylamide hydrogel substrates. Quantitative real-time RT-PCR, immunoblotting, and immunofluorescence microscopy were used to measure the expression, activity, and subcellular location of YAP and its downstream targets, respectively. Proliferation rates were examined in NLC and GLC cells by methyl thiazolyl tetrazolium salt assays, across a range of incrementally increased substrate stiffness. Endpoints were examined in the presence or absence of a YAP inhibitor, verteporfin (2 µM). RESULTS: GLC cells show significantly (P < 0.05) increased YAP gene expression and total-YAP protein compared to NLC cells, with significantly increased proliferation. YAP regulation is mechanosensitive, because NLC cells cultured on pathomimetic, stiff substrates (100 kPa) show significantly upregulated YAP gene and protein expression, increased YAP phosphorylation at tyrosine 357, reduced YAP phosphorylation at serine 127, increased nuclear pooling, and increased transcriptional target, connective tissue growth factor. Accordingly, myofibroblastic markers, α-smooth muscle actin (α-SMA) and collagen type I, alpha 1 (Col1A1) are increased. Proliferation rates are elevated on 50 kPa substrates and tissue culture plastic. Verteporfin treatment significantly inhibits YAP-mediated cellular activation and proliferation despite a stiffened microenvironment. CONCLUSIONS: These data demonstrate how YAP plays a pivotal role in LC cells adopting a profibrotic and proliferative phenotype in response to the stiffened LC present in aging and glaucoma. YAP provides an attractive and novel therapeutic target, and its inhibition via verteporfin warrants further clinical investigation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Murphy R, Irnaten M, Hopkins A, et al. Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma. Invest Ophthalmol Vis Sci. 2022. PMID: 35015027. doi:10.1167/iovs.63.1.16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。